129 related articles for article (PubMed ID: 38532630)
21. Gene therapy model of X-linked severe combined immunodeficiency using a modified foamy virus vector.
Horino S; Uchiyama T; So T; Nagashima H; Sun SL; Sato M; Asao A; Haji Y; Sasahara Y; Candotti F; Tsuchiya S; Kure S; Sugamura K; Ishii N
PLoS One; 2013; 8(8):e71594. PubMed ID: 23990961
[TBL] [Abstract][Full Text] [Related]
22. Combined lentiviral- and RNA-mediated CRISPR/Cas9 delivery for efficient and traceable gene editing in human hematopoietic stem and progenitor cells.
Yudovich D; Bäckström A; Schmiderer L; Žemaitis K; Subramaniam A; Larsson J
Sci Rep; 2020 Dec; 10(1):22393. PubMed ID: 33372184
[TBL] [Abstract][Full Text] [Related]
23. Faster T-cell development following gene therapy compared with haploidentical HSCT in the treatment of SCID-X1.
Touzot F; Moshous D; Creidy R; Neven B; Frange P; Cros G; Caccavelli L; Blondeau J; Magnani A; Luby JM; Ternaux B; Picard C; Blanche S; Fischer A; Hacein-Bey-Abina S; Cavazzana M
Blood; 2015 Jun; 125(23):3563-9. PubMed ID: 25869287
[TBL] [Abstract][Full Text] [Related]
24. Intrathymic injection of hematopoietic progenitor cells establishes functional T cell development in a mouse model of severe combined immunodeficiency.
Tuckett AZ; Thornton RH; O'Reilly RJ; van den Brink MRM; Zakrzewski JL
J Hematol Oncol; 2017 May; 10(1):109. PubMed ID: 28511686
[TBL] [Abstract][Full Text] [Related]
25. Self-inactivating gammaretroviral vectors for gene therapy of X-linked severe combined immunodeficiency.
Thornhill SI; Schambach A; Howe SJ; Ulaganathan M; Grassman E; Williams D; Schiedlmeier B; Sebire NJ; Gaspar HB; Kinnon C; Baum C; Thrasher AJ
Mol Ther; 2008 Mar; 16(3):590-8. PubMed ID: 18180772
[TBL] [Abstract][Full Text] [Related]
26. Targeted gene correction of human hematopoietic stem cells for the treatment of Wiskott - Aldrich Syndrome.
Rai R; Romito M; Rivers E; Turchiano G; Blattner G; Vetharoy W; Ladon D; Andrieux G; Zhang F; Zinicola M; Leon-Rico D; Santilli G; Thrasher AJ; Cavazza A
Nat Commun; 2020 Aug; 11(1):4034. PubMed ID: 32788576
[TBL] [Abstract][Full Text] [Related]
27. Gene therapy for PIDs: progress, pitfalls and prospects.
Mukherjee S; Thrasher AJ
Gene; 2013 Aug; 525(2):174-81. PubMed ID: 23566838
[TBL] [Abstract][Full Text] [Related]
28. The Combination of CRISPR/Cas9 and iPSC Technologies in the Gene Therapy of Human β-thalassemia in Mice.
Ou Z; Niu X; He W; Chen Y; Song B; Xian Y; Fan D; Tang D; Sun X
Sci Rep; 2016 Sep; 6():32463. PubMed ID: 27581487
[TBL] [Abstract][Full Text] [Related]
29. Targeted genome editing in human repopulating haematopoietic stem cells.
Genovese P; Schiroli G; Escobar G; Tomaso TD; Firrito C; Calabria A; Moi D; Mazzieri R; Bonini C; Holmes MC; Gregory PD; van der Burg M; Gentner B; Montini E; Lombardo A; Naldini L
Nature; 2014 Jun; 510(7504):235-240. PubMed ID: 24870228
[TBL] [Abstract][Full Text] [Related]
30. CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications.
Venkatesan V; Christopher AC; Karuppusamy KV; Babu P; Alagiri MKK; Thangavel S
J Vis Exp; 2022 Aug; (186):. PubMed ID: 36036597
[TBL] [Abstract][Full Text] [Related]
31. Genome editing of HBG1 and HBG2 to induce fetal hemoglobin.
Métais JY; Doerfler PA; Mayuranathan T; Bauer DE; Fowler SC; Hsieh MM; Katta V; Keriwala S; Lazzarotto CR; Luk K; Neel MD; Perry SS; Peters ST; Porter SN; Ryu BY; Sharma A; Shea D; Tisdale JF; Uchida N; Wolfe SA; Woodard KJ; Wu Y; Yao Y; Zeng J; Pruett-Miller S; Tsai SQ; Weiss MJ
Blood Adv; 2019 Nov; 3(21):3379-3392. PubMed ID: 31698466
[TBL] [Abstract][Full Text] [Related]
32. Challenges in Gene Therapy for Somatic Reverted Mosaicism in X-Linked Combined Immunodeficiency by CRISPR/Cas9 and Prime Editing.
Hou Y; Ureña-Bailén G; Mohammadian Gol T; Gratz PG; Gratz HP; Roig-Merino A; Antony JS; Lamsfus-Calle A; Daniel-Moreno A; Handgretinger R; Mezger M
Genes (Basel); 2022 Dec; 13(12):. PubMed ID: 36553615
[TBL] [Abstract][Full Text] [Related]
33. Transduction of human CD34+ repopulating cells with a self-inactivating lentiviral vector for SCID-X1 produced at clinical scale by a stable cell line.
Greene MR; Lockey T; Mehta PK; Kim YS; Eldridge PW; Gray JT; Sorrentino BP
Hum Gene Ther Methods; 2012 Oct; 23(5):297-308. PubMed ID: 23075105
[TBL] [Abstract][Full Text] [Related]
34. Polyclonal T-cell reconstitution of X-SCID recipients after in utero transplantation of lymphoid-primed multipotent progenitors.
Liuba K; Pronk CJ; Stott SR; Jacobsen SE
Blood; 2009 May; 113(19):4790-8. PubMed ID: 19074736
[TBL] [Abstract][Full Text] [Related]
35. Clinical translation of TALENS: Treating SCID-X1 by gene editing in iPSCs.
Biffi A
Cell Stem Cell; 2015 Apr; 16(4):348-9. PubMed ID: 25842973
[TBL] [Abstract][Full Text] [Related]
36. Immune Reconstitution After Gene Therapy Approaches in Patients With X-Linked Severe Combined Immunodeficiency Disease.
Blanco E; Izotova N; Booth C; Thrasher AJ
Front Immunol; 2020; 11():608653. PubMed ID: 33329605
[TBL] [Abstract][Full Text] [Related]
37. CRISPR/Cas9-Based Disease Modeling and Functional Correction of Interleukin 7 Receptor Alpha Severe Combined Immunodeficiency in T-Lymphocytes and Hematopoietic Stem Cells.
Rai R; Steinberg Z; Romito M; Zinghirino F; Hu YT; White N; Naseem A; Thrasher AJ; Turchiano G; Cavazza A
Hum Gene Ther; 2024 Apr; 35(7-8):269-283. PubMed ID: 38251667
[TBL] [Abstract][Full Text] [Related]
38. A novel model of SCID-X1 reconstitution reveals predisposition to retrovirus-induced lymphoma but no evidence of gammaC gene oncogenicity.
Scobie L; Hector RD; Grant L; Bell M; Nielsen AA; Meikle S; Philbey A; Thrasher AJ; Cameron ER; Blyth K; Neil JC
Mol Ther; 2009 Jun; 17(6):1031-8. PubMed ID: 19337236
[TBL] [Abstract][Full Text] [Related]
39. T cell dynamics and response of the microbiota after gene therapy to treat X-linked severe combined immunodeficiency.
Clarke EL; Connell AJ; Six E; Kadry NA; Abbas AA; Hwang Y; Everett JK; Hofstaedter CE; Marsh R; Armant M; Kelsen J; Notarangelo LD; Collman RG; Hacein-Bey-Abina S; Kohn DB; Cavazzana M; Fischer A; Williams DA; Pai SY; Bushman FD
Genome Med; 2018 Sep; 10(1):70. PubMed ID: 30261899
[TBL] [Abstract][Full Text] [Related]
40. Correction of SCID-X1 using an enhancerless Vav promoter.
Almarza E; Zhang F; Santilli G; Blundell MP; Howe SJ; Thornhill SI; Bueren JA; Thrasher AJ
Hum Gene Ther; 2011 Mar; 22(3):263-70. PubMed ID: 20887212
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
